Clinical trial to evaluate efficacy and safety of cyclophosphamide, bortezomib and dexamethasone (CBD) induction and autologous stem cell transplantation for patients for newly diagnosed multiple myeloma (NBMT-ASCT1201)

Trial Profile

Clinical trial to evaluate efficacy and safety of cyclophosphamide, bortezomib and dexamethasone (CBD) induction and autologous stem cell transplantation for patients for newly diagnosed multiple myeloma (NBMT-ASCT1201)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Dec 2015

At a glance

  • Drugs Bortezomib (Primary) ; Lenalidomide (Primary) ; Autologous stem cell therapy; Cyclophosphamide; Dexamethasone; Granulocyte colony-stimulating factors; Melphalan
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Dec 2015 Status changed from recruiting to active, no longer recruiting as reported by University Hospital medical Information Network - Japan.
    • 30 Jul 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top